1. Search Result
Search Result
Isoforms Recommended: BACE2
Results for "

BACE2

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

1

Recombinant Proteins

1

Click Chemistry

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-136742

    Beta-secretase Metabolic Disease
    BACE2-IN-1 (compound 3l) is a highly selective BACE2 inhibitor with a K i value of 1.6 nM. BACE2 inhibitors can be used to research of Type 2 Diabetes .
    BACE2-IN-1
  • HY-16759
    Verubecestat
    3 Publications Verification

    MK-8931

    Beta-secretase Neurological Disease
    Verubecestat (MK-8931) is an orally active, high-affinity BACE1 and BACE2 inhibitor with Ki values of 2.2 nM and 0.38 nM. Verubecestat effectively reduces Aβ40 and has the potential for Alzheimer's Disease [2].
    Verubecestat
  • HY-13240
    LY2886721
    2 Publications Verification

    Beta-secretase Neurological Disease
    LY2886721 is a potent, selective and orally active beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC50 of 20.3 nM for recombinant human BACE1. LY2886721 is selectivity against cathepsin D, pepsin, and renin, but lacking selectivity against BACE2 (IC50 of 10.2 nM). LY2886721 can across blood-brain barrier and has the potential for Alzheimer's disease treatment .
    LY2886721
  • HY-RS01336

    Small Interfering RNA (siRNA) Others

    BACE2 Human Pre-designed siRNA Set A contains three designed siRNAs for BACE2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    BACE2 Human Pre-designed siRNA Set A
    BACE2 Human Pre-designed siRNA Set A
  • HY-RS01337

    Small Interfering RNA (siRNA) Others

    Bace2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bace2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Bace2 Mouse Pre-designed siRNA Set A
    Bace2 Mouse Pre-designed siRNA Set A
  • HY-RS01338

    Small Interfering RNA (siRNA) Others

    Bace2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Bace2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Bace2 Rat Pre-designed siRNA Set A
    Bace2 Rat Pre-designed siRNA Set A
  • HY-16759B

    MK-8931 tosylate

    Beta-secretase Neurological Disease
    Verubecestat tosylate is an orally active, high-affinity BACE1 and BACE2 inhibitor with Ki values of 2.2 nM and 0.38 nM. Verubecestat tosylate effectively reduces Aβ40 and has the potential for Alzheimer's Disease [2].
    Verubecestat tosylate
  • HY-16759A

    MK-8931 TFA

    Beta-secretase Neurological Disease
    Verubecestat (MK-8931) TFA is an orally active, high-affinity BACE1 and BACE2 inhibitor with Ki values of 2.2 nM and 0.38 nM. Verubecestat TFA effectively reduces Aβ40 and has the potential for Alzheimer's Disease [2].
    Verubecestat TFA
  • HY-118098

    Beta-secretase Neurological Disease
    LY3202626 is a CNS penetrant BACE inhibitor with IC50s of 0.615 nM and 0.871 nM against BACE1 and BACE2, respectively .
    LY3202626
  • HY-13240A

    Beta-secretase Neurological Disease
    LY2886721 hydrochloride is a potent, selective and orally active beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC50 of 20.3 nM for recombinant human BACE1. LY2886721 hydrochloride is selectivity against cathepsin D, pepsin, and renin, but lacking selectivity against BACE2 (IC50 of 10.2 nM). LY2886721 hydrochloride can across blood-brain barrier and has the potential for Alzheimer's disease treatment .
    LY2886721 hydrochloride
  • HY-100182

    Beta-secretase Neurological Disease
    BACE1-IN-1 is a potent and highly brain penetrant BACE1 inhibitor with IC50s of 32 and 47 nM for human BACE1 and BACE2, respectively.
    BACE1-IN-1
  • HY-124322

    Beta-secretase Neurological Disease Inflammation/Immunology
    NB-360 is a potent, brain penetrable, and orally bioavailable dual BACE1/BACE2 inhibitor (IC50: mouse and human BACE1=5 nM; BACE2=6 nM). NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in amyloid precursor protein(APP) transgenic mice. NB-360 can completely block the progression of Aβ deposition in the brains of APP transgenic mice. NB-360 shows excellent selectivity over the related aspartyl proteases pepsin, cathepsin D and cathepsin E [2].
    NB-360
  • HY-128594

    Beta-secretase Neurological Disease
    BACE1-IN-4 is a potent and highly selective BACE1 inhibitor, with an IC50 of 3.8 nM and a Ki of 1.9 nM, more selective at BACE1 over BACE2. Anti-Alzheimer’s disease .
    BACE1-IN-4
  • HY-12938

    Beta-secretase Neurological Disease
    AMG-8718 is a potent, selective and orally active BACE1 inhibitor with IC50 values of 0.0007, 0.005 µM for BACE1 and BACE2, respectively. AMG-8718 significantly decreases Aβ40 levels in the CSF and brain .
    AMG-8718
  • HY-161359

    Beta-secretase Neurological Disease
    BACE1-IN-14 (compound 27f) is a BACE1 inhibitor, with the EC50 values of 0.7 μM and 1.6 μM for BACE1 and BACE2. BACE1-IN-14 is can be used in Alzheimer's disease (AD) research .
    BACE1-IN-14
  • HY-147758

    Beta-secretase Amyloid-β Neurological Disease
    BACE1/2-IN-1 (compound 34) is a potent BACE1 and BACE2 inhibitor, with an IC50 of 0.01 and 0.0053 μM, respectively. BACE1/2-IN-1 shows a combination of lower Pgp efflux ratio and improved passive permeability. BACE1/2-IN-1 displays reduced liver microsomal metabolic stability .
    BACE1/2-IN-1
  • HY-10472
    LY2811376
    Maximum Cited Publications
    11 Publications Verification

    Beta-secretase Neurological Disease
    LY2811376 is the first orally available non-peptidic β-secretase (BACE1) inhibitor with IC50 of 239 nM-249 nM, that acts to decrease Aβ secretion with EC50 of 300 nM, and demonstrates to have 10-fold selectivity towards BACE1 over BACE2, and more than 50-fold inhibition over other aspartic proteases including cathepsin D, pepsin, or renin.
    LY2811376
  • HY-128774

    Beta-secretase Neurological Disease
    AM-6494 is a potent and orally active BACE1 (efficacious β-site amyloid precursor protein cleaving enzyme 1) inhibitor (IC50=0.4 nM) with in vivo selectivity over BACE2 (IC50=18.6 nM) . AM-6494 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    AM-6494
  • HY-13438
    AZD3839 free base
    1 Publications Verification

    Beta-secretase Cancer
    AZD3839 free base is a potent and selective orally active, brain-permeable BACE1 inhibitor (Ki=26 nM). AZD3839 free base shows 14 and >1000-fold selectivity against BACE2 and cathepsin D, respectively. AZD3839 free base exhibits dose- and time-dependent lowering of plasma, brain, and cerebrospinal fluid Aβ levels in mouse, guinea pig, and non-human primate. AZD3839 free base can be used for the research of Alzheimer's disease [2].
    AZD3839 free base

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: